GREENWOOD VILLAGE, Colo.–(BUSINESS WIRE)–BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced the presentation of encouraging data from its Phase 2 study of lead candidate, BMX-001, for the treatment of high-grade glioma (HGG) at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting. In the Phase 2 study, BMX-001 in combination with radiotherapy (RT) and temozolomide (TMZ) demonstra
Click here to view original post
News
GHX Vendormate Partners with 360training to Drive Efficient Credentialing Processes for Healthcare Industry Representatives
New Integration Enhances Digital Credentialing by Providing Direct Access to Compliance Training Courses LOUISVILLE, Colo., June 12, 2023 /PRNewswire/ — Global Healthcare Exchange (GHX) announced a new strategic relationship with 360training that will give GHX […]
News
West Nile Virus Season Returns − a Medical Epidemiologist Explains How It’s Transmitted and How You Can Avoid It
West Nile virus is the most common mosquito-borne illness in the continental U.S., with an average of 2,464 reported cases per year. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech […]
News
STAT+: Pharma companies and their allies seek to exempt orphan drugs from state pricing limits
As more states create dedicated boards to cap the costs of medicines, some drugmakers and their allies are pushing back with a controversial tactic — lobbying for legislation to set exemptions for so-called orphan drugs, […]
